69.28
price down icon0.72%   -0.50
pre-market  プレマーケット:  70.43   1.15   +1.66%
loading
前日終値:
$69.78
開ける:
$70.93
24時間の取引高:
439.12K
Relative Volume:
0.73
時価総額:
$2.02B
収益:
$234.60M
当期純損益:
$-13.23M
株価収益率:
-133.08
EPS:
-0.5206
ネットキャッシュフロー:
$19.61M
1週間 パフォーマンス:
+4.80%
1か月 パフォーマンス:
+20.11%
6か月 パフォーマンス:
+92.44%
1年 パフォーマンス:
+234.20%
1日の値動き範囲:
Value
$68.39
$72.36
1週間の範囲:
Value
$60.70
$72.36
52週間の値動き範囲:
Value
$17.11
$73.30

Anaptysbio Inc Stock (ANAB) Company Profile

Name
名前
Anaptysbio Inc
Name
セクター
Healthcare (1106)
Name
電話
858-362-6295
Name
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Name
職員
104
Name
Twitter
@anaptysbio
Name
次回の収益日
2026-05-04
Name
最新のSEC提出書
Name
ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ANAB icon
ANAB
Anaptysbio Inc
69.28 2.02B 234.60M -13.23M 19.61M -0.5206
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 107.87B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 73.63B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 49.42B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 40.20B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.06B 5.36B 287.73M 924.18M 2.5229

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-10-13 開始されました Barclays Overweight
2025-06-04 アップグレード H.C. Wainwright Neutral → Buy
2025-02-04 開始されました Wolfe Research Outperform
2024-12-11 ダウングレード H.C. Wainwright Buy → Neutral
2024-12-02 ダウングレード BTIG Research Buy → Neutral
2024-07-22 開始されました H.C. Wainwright Buy
2024-07-19 アップグレード JP Morgan Neutral → Overweight
2024-04-16 開始されました Leerink Partners Outperform
2024-04-11 開始されました Wells Fargo Overweight
2024-03-12 アップグレード Wedbush Neutral → Outperform
2024-02-26 開始されました BTIG Research Buy
2024-02-21 開始されました Stifel Buy
2024-02-16 開始されました Piper Sandler Overweight
2023-05-22 アップグレード JP Morgan Underweight → Neutral
2023-05-18 開始されました TD Cowen Outperform
2023-01-06 ダウングレード Raymond James Outperform → Mkt Perform
2022-11-01 アップグレード Guggenheim Neutral → Buy
2022-09-19 再開されました H.C. Wainwright Buy
2022-09-13 ダウングレード Truist Buy → Hold
2022-09-01 開始されました Raymond James Outperform
2022-03-22 ダウングレード Guggenheim Buy → Neutral
2021-06-22 開始されました H.C. Wainwright Buy
2021-05-21 開始されました UBS Neutral
2021-03-16 アップグレード Truist Hold → Buy
2021-03-09 ダウングレード Wedbush Outperform → Neutral
2021-03-08 ダウングレード JP Morgan Overweight → Underweight
2021-02-11 アップグレード JP Morgan Underweight → Overweight
2020-10-27 アップグレード Wedbush Neutral → Outperform
2020-10-14 アップグレード Guggenheim Neutral → Buy
2019-11-08 ダウングレード JP Morgan Overweight → Underweight
2019-11-08 ダウングレード Jefferies Buy → Hold
2019-11-08 ダウングレード SunTrust Buy → Hold
2019-11-08 ダウングレード Wedbush Outperform → Neutral
2019-06-21 ダウングレード Credit Suisse Outperform → Neutral
2019-06-21 ダウングレード Stifel Buy → Hold
2018-12-20 開始されました H.C. Wainwright Buy
2018-11-21 開始されました JP Morgan Overweight
2018-07-19 開始されました Credit Suisse Outperform
2018-04-04 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2018-03-27 繰り返されました Stifel Buy
2018-03-06 繰り返されました Stifel Buy
2018-02-15 繰り返されました SunTrust Buy
2018-01-23 繰り返されました Credit Suisse Outperform
2017-11-15 開始されました SunTrust Buy
2017-11-09 開始されました Jefferies Buy
2017-10-11 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
すべてを表示

Anaptysbio Inc (ANAB) 最新ニュース

pulisher
May 05, 2026

AnaptysBio (NASDAQ:ANAB) Reaches New 52-Week HighHere's Why - MarketBeat

May 05, 2026
pulisher
May 05, 2026

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance

May 05, 2026
pulisher
May 04, 2026

Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $93 - Moomoo

May 04, 2026
pulisher
May 04, 2026

GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation - MSN

May 04, 2026
pulisher
May 04, 2026

ANAB Maintained by Piper Sandler -- Price Target Lowered to $93 - GuruFocus

May 04, 2026
pulisher
May 04, 2026

AnaptysBio CEO to appear at royalty company virtual conference - Stock Titan

May 04, 2026
pulisher
May 04, 2026

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - GlobeNewswire

May 04, 2026
pulisher
May 04, 2026

Biotech Momentum Builds Around AnaptysBio Shift - Kalkine Media

May 04, 2026
pulisher
May 04, 2026

Piper Sandler Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat

May 04, 2026
pulisher
May 03, 2026

AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute - Yahoo Finance

May 03, 2026
pulisher
May 02, 2026

AnaptysBio stock rallies as Delaware court tosses Tesaro breach claim - MSN

May 02, 2026
pulisher
May 02, 2026

AnaptysBio, Inc. (ANAB) may report negative earnings: Know the trend ahead of Q1 release - MSN

May 02, 2026
pulisher
May 02, 2026

AnaptysBio (NASDAQ:ANAB) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill

May 02, 2026
pulisher
May 01, 2026

AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 14.7% in April - MarketBeat

May 01, 2026
pulisher
May 01, 2026

ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill

May 01, 2026
pulisher
Apr 29, 2026

AnaptysBio rises after completing First Tracks spinoff - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

Director Susannah Gray receives 11,250 RSUs at AnaptysBio (ANAB) - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Barclays Initiates Coverage of AnaptysBio (ANAB) with Overweight Recommendation - MSN

Apr 29, 2026
pulisher
Apr 28, 2026

ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 28, 2026
pulisher
Apr 28, 2026

AnaptysBio (ANAB) surges 14.8%: Is this an indication of further gains? - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Rare skin disease drug study appears in NEJM Evidence before FDA date - Stock Titan

Apr 28, 2026
pulisher
Apr 28, 2026

AnaptysBio (NASDAQ: ANAB) details spin-off, pay and board changes - Stock Titan

Apr 28, 2026
pulisher
Apr 28, 2026

Fenwick Secures Chancery Court Victory for AnaptysBio in Licensing Dispute - fenwick.com

Apr 28, 2026
pulisher
Apr 28, 2026

ANAB Rated Outperform by Leerink Partners -- Price Target Raised to $85 - GuruFocus

Apr 28, 2026
pulisher
Apr 28, 2026

AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighTime to Buy? - MarketBeat

Apr 28, 2026
pulisher
Apr 28, 2026

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - Sahm

Apr 28, 2026
pulisher
Apr 27, 2026

Why Is AnaptysBio Stock Soaring Monday?AnaptysBio (NASDAQ:ANAB) - Benzinga

Apr 27, 2026
pulisher
Apr 27, 2026

AnaptysBio (NASDAQ:ANAB) Trading 11.2% HigherTime to Buy? - MarketBeat

Apr 27, 2026
pulisher
Apr 27, 2026

GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation (GSK:NYSE) - Seeking Alpha

Apr 27, 2026
pulisher
Apr 27, 2026

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance

Apr 27, 2026
pulisher
Apr 27, 2026

AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains? - Yahoo Finance

Apr 27, 2026
pulisher
Apr 27, 2026

GSK (NYSE: GSK) outlines TESARO–AnaptysBio dostarlimab litigation status and Jemperli growth - Stock Titan

Apr 27, 2026
pulisher
Apr 27, 2026

AnaptysBio (ANAB) Expected to Announce Earnings on Monday - MarketBeat

Apr 27, 2026
pulisher
Apr 27, 2026

GSK Subsidiary Wins Motion Against AnaptysBio in Contract Dispute - GuruFocus

Apr 27, 2026
pulisher
Apr 27, 2026

GSK Subsidiary TESARO Faces Setback in AnaptysBio Litigation, Jemperli Growth Remains Strong - AskTraders

Apr 27, 2026
pulisher
Apr 27, 2026

Court favors AnaptysBio dismissing anticipatory breach claim - The Pharma Letter

Apr 27, 2026
pulisher
Apr 27, 2026

GSK subsidiary wins dismissal of AnaptysBio anticipatory breach claim (GSK:NYSE) - Seeking Alpha

Apr 27, 2026
pulisher
Apr 27, 2026

TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation - GSK

Apr 27, 2026
pulisher
Apr 27, 2026

GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio - Proactive financial news

Apr 27, 2026
pulisher
Apr 27, 2026

US court rules against GSK in dispute with AnaptysBio - Sharecast.com

Apr 27, 2026
pulisher
Apr 27, 2026

GSK says unit Tesaro's claim for declaratory judgment against AnaptysBio unchanged - marketscreener.com

Apr 27, 2026
pulisher
Apr 26, 2026

AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 26, 2026
pulisher
Apr 25, 2026

AnaptysBio Completes Spin-Off of First Tracks Biotherapeutics: Key Financial Impacts and Pro Forma Results - Minichart

Apr 25, 2026
pulisher
Apr 25, 2026

Delaware court dismisses Tesaro breach claim against AnaptysBio By Investing.com - Investing.com Australia

Apr 25, 2026
pulisher
Apr 25, 2026

AnaptysBio (NASDAQ:ANAB) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Apr 25, 2026
pulisher
Apr 24, 2026

GSK Faces Legal Setback as AnaptysBio Wins Court Ruling - GuruFocus

Apr 24, 2026

Anaptysbio Inc (ANAB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):